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Abstract
Background: Cutaneous Leishmaniasis is a worldwide disease, endemic in 88 countries, that has
shown an increasing incidence over the last two decades. So far, pentavalent antimony compounds
have been considered the treatment of choice, with a percentage of cure of about 85%. However,
the high efficacy of these drugs is counteracted by their many disadvantages and adverse events.
Previous studies have shown nitric oxide to be a potential alternative treatment when administered
topically with no serious adverse events. However, due to the unstable nitric oxide release, the
topical donors needed to be applied frequently, making the adherence to the treatment difficult.
The electrospinning technique has allowed the production of a multilayer transdermal patch that
produces a continuous and stable nitric oxide release. The main objective of this study is to evaluate
this novel nitric oxide topical donor for the treatment of cutaneous leishmaniasis.
Methods and design: A double-blind, randomized, double-masked, placebo-controlled clinical
trial, including 620 patients from endemic areas for Leishmaniasis in Colombia was designed to
investigate whether this patch is as effective as meglumine antimoniate for the treatment of
cutaneous leishmaniasis but with less adverse events. Subjects with ulcers characteristic of
cutaneous leishmaniasis will be medically evaluated and laboratory tests and parasitological
confirmation performed. After checking the inclusion/exclusion criteria, the patients will be
randomly assigned to one of two groups. During 20 days Group 1 will receive simultaneously
meglumine antimoniate and placebo of nitric oxide patches while Group 2 will receive placebo of
meglumine antimoniate and active nitric oxide patches. During the treatment visits, the medications
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will be daily administered and the presence of adverse events assessed. During the follow-up, the
research group will visit the patients at days 21, 45, 90 and 180. The healing process of the ulcer,
the health of the participants, recidivisms and/or reinfection will also be assessed. The evolution of
the ulcers will be photographically registered. In case that the effectiveness of the patches is
demonstrated, a novel and safe therapeutic alternative for one of the most important public health
problems in many countries will be available to patients.
Background
Cutaneous Leishmaniasis (CL) is a worldwide disease that
is endemic in 88 countries [1]. It is estimated that 1.5 mil-
lion people suffer from CL annually and that more than
350 million are at risk of contracting the infection [2-4].
In America, 60,000 new cases of CL are reported annually
[5], being endemic in 20 of its 22 countries and in 2
islands of the Caribbean [2]. Currently, CL has affected
more than 500 U.S. Army soldiers serving in Iraq [6]. In
the Andean region, the incidence of Leishmaniasis has
been increasing dramatically over the last two decades;
reaching more than 14,000 cases per year from 1996–98
[7]. In Colombia 6,500 cases have been reported [8]. The
increase in the reported cases of CL in Colombia has been
related to factors such as migration, deforestation, the
multiplication of illicit plantations, the armed political
conflict and the behavioral changes of the vector. The
main strains of Leishmania in Colombia are L. panamensis,
L. brazilensis, L. infantum and L. guyanensis, which are dis-
tributed throughout the entire national territory, predom-
inantly in the rural areas [9]. CL is caused by intracellular
protozoan parasites of the genus Leishmania [1] and is
transmitted to humans through the bite of a small per-
centage of the species of phlebotomus and lutzomyia
sandflies classified to date [9]. In the digestive system of
the sandflies, this dimorphic parasite presents an extracel-
lular flagellated form called a promastigote, which upon
its release in the host blood, is phagocyted by the macro-
phage, losing its flagella and turning into an amastigote
[10]. Dogs, rodents and didelphidae are the natural hosts
of the parasite while man is an incidental host [11]. This
zoonosis has suffered an interesting urbanization phe-
nomenon, changing from an eminent rural entity affect-
ing mainly men of an active age, to a disease that is
affecting all people, especially children [8,12]. The charac-
teristic lesions of this disease are ulcers that heal sponta-
neously over a period of three months to a year,
depending on the isolate, and that leave a flat, atrophic
and depigmented scar [13-15]. The CL, especially the one
produced by L. brazilensis can evolve into mucocutaneous
Leishmaniasis (MCL), which has a worse prognosis owing
to the deforming character of its lesions [16]. The sponta-
neous cure of these lesions allows for the acquisition of
partial resistance to reinfection, which could explain the
higher pathogenicity observed in the children and young
adult population [12]. Previous studies have shown a
higher incidence of CL and a poor response to treatment
in the children population [17]. The program of epidemi-
ological vigilance in Colombia requires that the probable
cases of CL (identified by ulcer features and by the
patient's origin) be confirmed by microscopic direct
examination of a secession sample obtained from the
ulcer, if these are negative, by biopsy of the wound. Once
confirmed, the cases must be notified to the Local Health
Secretary using clinical-epidemiological records. This
institution, in charge of the epidemiological vigilance,
studies the sources of transmission and distributes the
medication to the people affected. Currently, various
aspects are considered when treating CL, among which,
the risk of developing MCL, the grade, localization,
number, size, evolution and persistence of the lesions, are
the most important [18]. For more than 60 years, the pen-
tavalent antimony compounds: sodium stibogluconate,
(Pentostan®, produced by Glaxo-Wellcome) and meglu-
mine antimoniate, (Glucantime®, produced by Sanofi-
Aventis) have been considered the treatments of choice
for this disease [19]. Studies made in Colombia reported
a percentage of cure of 85%, using meglumine antimoni-
ate [20,21]. Despite the efficacy of these drugs is high, they
present many disadvantages such as parenteral adminis-
tration, and, reversible secondary effects such as nausea,
vomiting, muscular and abdominal pain, cardiac prob-
lems, a rise in the concentration of hepatic aminotrans-
ferases, and chemical pancreatitis [22,23]. Additionally,
the adherence to the treatment is affected by its duration
(several weeks) and its availability by the restriction in its
distribution. Therapeutic alternatives of second line have
been proposed; amphotericin B and pentamidine have
been used with excellent results, nevertheless their high
cost, little availability, the necessity to hospitalize the
patients for their administration and the severity of their
secondary effects have limited their use [23,24]. In the last
decade new treatments for CL have been developed, using
oral agents such as mefloquine, itraconazole, miltefosine,
paromomycin, ketoconazole, allopurinol and dapsone,
however, they have not shown enough evidence of their
effectiveness [19,21,25,26]. In an effort to develop a topi-
cal treatment for CL, paromomycin has been used in dif-
ferent preparations. However, healing rates achieved with
this medication have not been higher than conventional
treatments, even when compared with placebo [27,28]. In
several studies, in vitro and in vivo, it has been demon-Trials 2006, 7:14 http://www.trialsjournal.com/content/7/1/14
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strated that nitric oxide (NO) is effective to eliminate var-
ious strains of Leishmania in its amastigote form [29-35].
The production of NO from the oxidation of L-arginine
caused by the inducible nitric oxide synthase (iNOS) con-
stitutes one of the most important defense mechanisms of
the macrophages [36], in which two oxidative forms of
defense against Leishmania have been identified. During
the first phase of infection, in response to the phagocyto-
sis process, some promastigotes are eliminated due to the
release of the superoxide ion, a process which is catalyzed
by the NADPH oxidase [29]. Those promastigotes that
survive this defense mechanism evolve into amastigotes,
activating the production of IL-12 in the macrophages and
promoting the presentation of the antigens of Leishmania
[29] to the T helpers 1 lymphocytes that enhance the cyto-
toxic activities of the macrophages toward the intracellu-
lar parasites via the interferon gamma (INFγ) and the
tumor necrosis factor alpha (TNFα) by promoting the
production of NO catalyzed by iNOS [31-33]. A recent
study shows a higher activity of iNOS in the macrophages
of subjects infected with CL, suggesting a vital role of NO
in the immunological activity against Leishmania [34]. In
Studies with rodents resistant to Leishmania  infection
(C57BL/6), where L. major, L. chagasi or L. donovani were
inoculated, the application of iNOS inhibitors like NG-
monomethyl-L-arginine (L-NMMA) caused a higher rate
of survival and virulence of the parasites in macrophages
[33,35,37,38]. After inoculating L. major in mice with the
genetic susceptibility to develop infections with Leishma-
nia (BALB/C), no activity of iNOS was observed. However,
the application of IL-12, was able to control the infection
by activating iNOS [31]. In humans, several clinical trials
have been realized with topical treatments containing NO
donors [39,40]. In Ecuador, our group developed and
tested a NO generating topical cream with S-nitroso-N-
acetylpenicillamine (SNAP), evidencing a beneficial effect
in the management of this type of ulcers with no reports
of any serious adverse event.
Nevertheless, due to the unstable nitric oxide release, the
cream had to be applied frequently (4 times a day) mak-
ing the adherence to the treatment difficult [39]. In Syria,
another group used potassium nitrate acidified with sali-
cylic acid and ascorbic acid for the topical treatment of L.
tropica [40]. In vitro, this NO generating mixture destroyed
the amastigotes and promastigotes of Leishmania; how-
ever, in vivo, the study of 40 patients presented inconsist-
ent results, reducing the size of the ulcer in 28% of the
subjects and healing only 12%. The discrepancy in these
results is believed to be due to the technique used to
obtain the NO. The acidification of nitrite produces an
instant blast of NO, but its release is not maintained over
a long period of time[40]. The difficulty of controlling the
liberation of NO has created the necessity of looking for
new techniques to regulate its release. The nanofiber pol-
ymers produced by the electrospinning technique have
been studied in order to guarantee the constant release of
pharmaceuticals on the lesion. In the electrospinning
process, a high voltage is used to create an electrically
charged jet of polymer solution, which dries and solidifies
to leave behind a dry polymer fiber [41]. As this jet travels
through the air, the solvent evaporates leaving behind a
charged fiber that can be electrically deflected and col-
lected on a metal screen [42,43]. Fibers with a variety of
cross sectional shapes and sizes are produced from differ-
ent polymers. With this technique, the encapsulation or
entrapment of several pharmaceuticals, enzymes and pro-
teins has been successful. In a previous study, nanofiber
patches were successfully used as releasing vehicles of tet-
racycline hydrochloride. The release of tetracycline was
constant for a period of 5 days [41,43]. Using the same
model, a multilayer transdermal patch has been pro-
duced, in which nitrite is bound to an ion exchange resin
(DOWEX) and electrospun into a polyurethane nanofib-
ers layer. A solution containing Waterlock® superabsorb-
ent and polyurethane is electrospun on top of the nitrite-
DOWEX layer. The ascorbic acid entrapped in the poly-
urethane solution is electrospun onto a third layer, with
another layer of Waterlock®  superabsorbent and poly-
urethane as the fourth and final one. Upon hydration, this
Nitric Oxide Releasing Patch (NOP) produces a stable
release of 3.5 µmol of NO during 12 hrs [41,44,45]. In a
pilot study, developed in Landazuri, Santander, Colom-
bia, a placebo-controlled clinical trial was conducted with
35 patients who presented 68 ulcers produced by L. pana-
mensis. Using the NOP, a 65% improvement was observed
in the treated ulcers, with only a 25% improvement in the
placebo group (p = 0.001). In this pilot study the unique
adverse event described was pruritus in the area where the
patch was applied (unpublished data). Taking into
account the wide distribution of CL, the changes in its
form of transmission and the difficulty related with the
availability of medication, this study proposes to investi-
gate whether the NO donor transdermal patch, produced
by electrospinning is, at least, as effective as the meglu-
mine antimoniate for the treatment of CL, with less
adverse events and a lower cost, constituting therefore an
effective therapeutic alternative. In case that the effective-
ness of the NOP is demonstrated in this study, a novel and
safe therapeutic alternative of easy access and higher
adherence for one of the most important public health
problems in our country will be made available.
Objectives
General objective
To evaluate the effectiveness and safety of NOP in the
treatment of CL compared with meglumine antimoniate
(Glucantime®).Trials 2006, 7:14 http://www.trialsjournal.com/content/7/1/14
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Specific objectives
1. To evaluate the healing rate of CL ulcers using a NOP
compared with the plan of treatment with meglumine
antimoniate recommended by the health ministry.
2. To identify adverse events associated with the applica-
tion of NOP and compare them with the ones produced
by the treatment with meglumine antimoniate.
3. To identify and compare the recidivisms that may occur
with both NOP and meglumine antimoniate.
4. To advance in the search of a therapeutic alternative for
CL in Colombia.
Design
Double blind, randomized, double-masked, placebo-con-
trolled clinical trial, comparing nitric oxide releasing
patches with meglumine antimoniate.
Sample size
The sample was calculated according to the arccosine for-
mula using a power of 80% and a type 1 error of 0.05%.
Assigning a successful rate of 85% for meglumine antimo-
niate and 75% for NOP, 558 patients will be needed. After
adjustment for a loss rate of 5%, the total of patients that
must be recruited is 620 (310 patients per treatment
group).
Population
The population will be composed from two regions of
Colombia. The first one is an endemic zone in Santander,
Colombia, located between the Magdalena Valley and the
East Mountain Range, which includes the municipalities
of Landazuri, El Carmen, San Vicente, El Playon and Rion-
egro. The second region is an endemic zone in North
Tolima, which includes the municipalities of Chaparral,
San Antonio, Libano, Falan, Palocabildo and Mariquita.
Selection of the patients
Inclusion criteria
1. Men and women between 18 and 50 years old
2. Cutaneous ulcers of more than two weeks of evolution
3. Positive parasitological diagnosis for CL
4. Patients that voluntarily accept to participate in the
study and sign the informed consent.
5. Disposition to attend all the visits punctually (initial,
treatment and follow-up)
6. Acceptation of not using any other treatment for CL
while in the study
Exclusion criteria
1. Pregnant women
2. Presence of any condition or disease that compromises
the patient immunologically (ie. diabetes, cancer, etc.) or,
any other, that, based on the judgment of the researcher,
could alter the course of CL.
3. Diffuse CL or more than five active lesions.
4. Mucocutaneous leishmaniasis (no lesion must be
located less than 2 cm from the nasal, uro-genital, and/or
anal mucous membranes or from the edge of the lips).
5. Visceral leishmaniasis.
6. Complete or incomplete treatment with antimony
compounds in the last three months.
7. Patients with history of hepatic, renal or cardiovascular
disease.
8. Mentally or neurologically disabled patients that are
considered not fit to approve their participation in the
study.
Study development
Logistic phase
This phase will last 4 months and will include the follow-
ing activities:
1. Training of the personnel that will participate in the
study.
2. Acquisition of the materials required for the develop-
ment of the project.
3. Elaboration of flyers, promotional and educative mate-
rial, procedures manual and case report forms (CRFs).
4. Treatment randomization.
The treatment randomization will be realized by the epi-
demiologist of the Cardiovascular Foundation of Colom-
bia. This randomization will be done in blocks in order to
keep the size of the treatment groups similar, to avoid
long sequences of the same treatment and to balance
when possible some of the bias inherent to the simple
randomization process. Additionally, this randomization
in blocks will facilitate the execution of interim analyses.
Recruitment phase
This phase will take 22 months. In the selected municipal-
ities, the health personnel that work in hospitals and
health centers will receive training regarding the diseaseTrials 2006, 7:14 http://www.trialsjournal.com/content/7/1/14
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and the study methodology. Simultaneously an epidemi-
ological focus study will be done with the leaders of the
community and the health personnel to identify the geo-
graphic and demographic conditions with the purpose of
developing strategies for the recruitment of possible cases
of leishmaniasis. Subsequently, the subjects that present
active ulcers with more than 2 weeks of evolution, with or
without parasitological confirmation of CL, will be
invited by the health promoters to attend the screening
visit (Table 1).
Screening visit
During this visit a complete clinical history will be elabo-
rated and data about antecedents of leishmaniasis
obtained (administered treatment, localization, number
of lesions, etc). A full medical evaluation will be realized
based on universally accepted techniques. The inclusion/
exclusion criteria will be applied and the selected candi-
dates informed about the study after which they will sign
an informed consent. For those subjects with ulcers of
more than two weeks of evolution without parasitological
diagnosis a direct test will be performed by the parasitol-
ogist. If the first direct test is negative, it will be repeated
up to three times; after which, in case of negative results,
a biopsy will be performed. In case leishmaniasis is not
confirmed the patient will be remitted to the original
health center.
Initial visit
The included patients will be randomly assigned in one of
two groups. A culture in Novy-Nicolle-McNeal (NNN)
medium will be taken for strain identification and a blood
sample withdrawn from the antecubital vein for hepatic
enzymes, creatinine, and pancreatic amylase determina-
Table 1: Schedule of activities
PROTOCOL 
ACTIVITIES
Screening 
Visit
Initial Visit Treatment 
visits
Follow-up visits
Visit 1 Visit 2 Visit 3 Visit 4
SCHEDULE 
OF VISITS
0 1–20 21+3 45 ± 7 90 ± 14 180 ± 14
Clinical History X X X X X X
Physical 
Examination
XX XXXX
Inclusion/
Exclusion 
criteria
X
Informed 
Consent
X
Direct test X
Sampling of 
cultures
X
Laboratory 
tests
XX
Randomization X
Treatment 
administration
XX
Clinical 
assessment of 
the lesion
XXXXXXX
Measurement of 
ulcers
XX X X X
Photographic 
registration
XX X X X
Education of 
patients
XXXXXXX
Handing over of 
diary
X
Evaluation of 
effectiveness
XXXX
Documentation 
of adverse 
events
XXXXXXX
Recording of 
concomitant 
medications
XXXXXXXTrials 2006, 7:14 http://www.trialsjournal.com/content/7/1/14
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tion. During this visit, a complete medical evaluation will
be performed, the ulcer will be measured and a picture
will be taken. Before taking the picture, a graduated rule
will be placed next to the ulcer along with a sticker marked
with the identification code of the participant, and the
date of the visit. The first NOP (active or placebo) will be
applied covering the lesion and the first shot of meglu-
mine antimoniate (active or placebo) administered. The
patients will receive information on how not to damage
the patches and how to identify and report adverse events.
To help the patients to do so, they will receive a diary to
register them. The two groups randomly composed will be
divided as follows:
Group 1: During 20 days this group will receive simulta-
neously intramuscular (IM) meglumine antimoniate
(Glucantime® 20 mg/kg/day with a maximum dose of 3
ampoules per day); and an NOP placebo.
Group 2: During 20 days this group will receive simulta-
neously placebo of IM meglumine antimoniate (5–15 cc/
day) and an active NOP.
Treatment visits
The patients will visit the health center daily during 20
days to receive both the NOP (placebo or active) and meg-
lumine antimoniate (placebo or active). Daily, the sub-
jects and their adherence to the treatment will be assessed
and the data collected. If any adverse event is detected, the
patient will be referred immediately to the medical staff
that will make an evaluation and report it to the adverse
event committee that will take the final decision in each
case.
Follow-up visits
This phase will last 10 months. During the follow-up, the
patients will be seen by the research group in 4 opportu-
nities. The first visit will take place the day after the end of
the treatment (day 21) in which new blood samples will
be taken for biochemical determinations. The second,
third and fourth visits will be realized on day 45, 90 and
180 respectively. During these visits the healing process of
the ulcer, the presence of recidivisms and/or reinfection
and the health of the participants will be assessed. The
evolution of the ulcers will be photographically registered.
The maximum and minimum diameters of the ulcer will
be measured using a graduated ruler, and the induration
using the ballpoint pen technique. The ulcer and indura-
tion areas will be calculated separately, and then regis-
tered in the CRF. The evaluation of the clinical response
will be based on the ulcer showing the least improvement.
1. Complete clinical response: Complete reepithelization
of the ulcer and disappearance of the induration.
2. Clinical Improvement: Reduction of more than 50% of
the ulcer and the induration areas in relation to the last
clinical evaluation.
3. Absence of clinical response: Increase or reduction of
less than 50% of the ulcer and the induration areas in rela-
tion to the last clinical evaluation.
4. Therapeutic failure:
a. Increase in the size of the ulcer by more than 50% in
relation to the last clinical evaluation
b. Presence of the ulcer three months after the beginning
of the treatment.
c. Reactivation: Appearance of a lesion on the edge or in
the center of the scar, with positive parasitological diagno-
sis, after a period of complete reepithelization.
d. Affection of the mucous membranes: Presence of affec-
tions of the mucous membranes during the treatment, at
the end of it or in the follow-up visits.
5. Reinfection: Activation of an ulcer in an area different
from the original lesion.
For subjects whose treatment will have been considered a
failure the code will be broken and they will be remitted
to their original health center to look for other therapeutic
approach.
Procedures
Physical examination
A complete physical examination will be realized and vital
signs will be measured.
Blood samples withdrawn
Blood samples will be withdrawn from the antecubital
vein to perform the following biochemical analyses:
1. Creatinine by spectrophotometry
2. Alanine transaminase (ALT) by spectrophotometry
3. Aspartate transaminase (AST) by spectrophotometry
4. Pancreatic amylase by spectrophotometry
Sampling technique for the direct test of CL
A direct test is performed to confirm the presence of cells
with amastigotes in a dermis scrape [46,47]; the sample
must be, in so far as it is possible, free of blood, cellular
detritus or pus. If the patients present several lesions, the
sample must be taken from the one with the shortest timeTrials 2006, 7:14 http://www.trialsjournal.com/content/7/1/14
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Table 2: Toxicity grading scale for determining the severity of clinical adverse events
SYSTEMIC
Grade 1 (Mild) Grade 2 (Moderate) Grade 3* (Severe) Grade 4* (Life-
threatening)
Fever: oral1 38 – 38.5°C 38.6 – 39.5°C 39.6 – 40.5°C >40.5°C
Headache1 Mild; no Rx required Transient, moderate; Rx 
required
Severe; responds to initial 
narcotic Rx
Intractable; required 
repeated narcotic Rx
Allergic reaction1 Pruritus without rash Localized urticaria Generalized urticaria; 
angioedema
Anaphylaxis
GASTROINTESTINAL
Nausea1 Mild discomfort; maintains 
reasonable intake
Moderate discomfort; 
intake decreased 
significantly; some activity 
limited
Severe discomfort; no 
significant intake; activities 
limited
Minimal fluid intake
Vomiting2 1 episode in 24 hours 2 – 5 episodes in 24 hours > 6 episodes in 24 hours or 
needing IV fluids
Physiologic consequences 
requiring hospitalization or 
parenteral nutrition
Diarrhea2 Mild or transient; 3–4 
loose stools/day or mild 
diarrhea lasting < 1 week
Moderate or persistent; 5–
7 loose stools/day or 
diarrhea lasting > 1 week.
>7 loose stools/day or 
bloody diarrhea; or 
orthostatic hypotension or 
electrolyte imbalance or >2 
LIV fluids required
Hypotensive shock or 
physiologic consequences 
requiring hospitalization
Oral discomfort2 Mild discomfort; no 
difficulty swallowing
Some limits on eating/
drinking
Eating/talking very limited; 
unable to swallow solid 
food
Unable to drink fluids; 
requires IV fluids
CARDIOVASCULAR
Cardiac rhythm2 ---- Asymptomatic, transient 
signs, no Rx required
Recurrent/persistent 
symptomatic Rx required
Unstable dysrythmia; 
hospitalization and Rx 
required
Hypertension1 Transient increase > 20 
mmHg; no Rx
Recurrent, chronic > 20 
mmHg, Rx required
Requires acute Rx; no 
hospitalization
Requires hospitalization
Hypotension1 Transient orthostatic 
hypotension, no Rx
Symptoms corrected with 
oral fluids
Requires IV fluids; no 
hospitalization required
Requires hospitalization
MUSCULOSKELETAL
Arthralgia2(joint pain) Mild pain not interfering 
with function
Moderate pain, analgesics 
and/or pain interfering with 
function but not with ADL
Severe pain; pain and/or 
analgesics interfering with 
ADL
Disabling pain
Myalgia2 Myalgia with no limitation 
of activity
Muscle tenderness (at 
other than injection 2site) 
or with moderate 
impairment of activity
Severe muscle tenderness 
with marked impairment of 
activity
Frank myonecrosis
RESPIRATORY
Cough3 Mild, relieved by non-
prescription medication 
only
Symptomatic requiring 
narcotic prescription 
medication
Symptomatic and 
significantly interfering with 
sleep or ADL
NA
Dyspnea3 Dyspnea on exertion, but 
can walk one flight of stairs 
without stopping
Dyspnea on exertion, but 
unable to walk 1 flight of 
stairs or 1 city block (0.1 
Km) without stopping
Dyspnea interfering with 
ADL
Dyspnea at rest requiring 
oxygen therapy; intubation/
ventilator indicated
1 = WHO Toxicity Grading Scale; 2 = DMID, NIH, Adult Toxicity Table; 3 = CTCAE v3.0; *Report Grade 3 and Grade 4 adverse events to the 
investigators in charge.
ADL: Activities of daily living
Ref: Toxicity Grading based on CTCAE v3.0 DCTD, NCI, NIH, DHHS December 12, 2003 http://ctep.cancer.gov.Trials 2006, 7:14 http://www.trialsjournal.com/content/7/1/14
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of evolution, the biggest induration area and/or the least
purulent discharge. If the lesion has a scab it must be
removed to improve the quality of the sample. The sample
can be taken from the active edge or from the bottom of
the ulcer. When the sample is taken from the active edge
asepsis must be realized with alcohol at 70% and hemos-
tasis then performed using the first and second fingers to
make sure that there is no blood in the sample. A small
incision of about 3 mm in length and depth is made with
a scalpel in the active edge parallel to the edge of the ulcer.
With the sharp side of the scalpel, a scrape is done in the
dermic wall of the incision to obtain tissue. The extracted
material is extended on two microscope slides. The sam-
ple is dried at room temperature, and then fixed with
methanol and stained with Giemsa, Wright or Field.
Using immersion oil the sample is observed under a
microscope with a 100× lens, the presence of amastigotes
of  Leishmania  assessed and their structure verified
(nucleus, kinetoplast and cell membrane). If the sample is
taken from the center of the lesion the same hemostatic
technique must be used, the scab removed, and the bot-
tom of the ulcer well cleaned using the sharp side of the
scalpel to prevent the presence of cellular detritus and/or
purulent material. This procedure must be continued
until the granulomas are seen at the bottom. With the
same technique used to process the samples from the
active edge the presence of amastigotes of Leishmania is
verified.
Technique for the sampling of cultures
The sample for the culture may be obtained by suctioning
the ulcer active edge or by extracting a fragment of tissue
which is then macerated in a phosphate-buffered saline
solution (PBS) with antibiotics (1000 UI of crystalline
penicillin per cc), before it is put in the culture medium.
A tuberculin syringe with a thin needle (26G), containing
0.3 cc of PBS solution with antibiotics is used in the suc-
tion technique. Previous asepsis of the ulcer with alcohol
at 70%, a needle is introduced into the dermis and
through rotating movements a small amount of tissue is
macerated by the needle bevel during about a minute,
after which it is suctioned into the syringe. The sample is
deposited in aseptic conditions into a NNN culture
medium and incubated at 26°C during 4 weeks [48,49].
Every week a drop is extracted from the culture medium
and placed between two slides to be observed under a
microscope. In case that promastigotes are not found, the
cultures are rejected as negative [46]. The strains are iden-
tified by species using the monoclonal antibodies devel-
oped by Dr. Diane Mc Mahon Pratt [50, 51]
Evaluation and management of adverse events
During the treatment and the follow-up visits, the patients
will be asked about adverse events. Each adverse event will
be classified by the physician as serious or non-seri-
ous(Table 2 and Table 3). A serious adverse event should
meet one or more of the following criteria:
1. Death
2. Life-threatening (i.e., immediate risk of death)
3. In-patient hospitalization or prolongation of existing
hospitalization
4. Persistent or significant disability/incapacity
The presence of a serious adverse event that puts the
patient's life at risk and/or requires immediate medical or
surgical procedure will call for the discontinuation of the
treatment and the initiation of the pertinent medical man-
agement of the patients. The investigator will notify the
Adverse Event Committee (AEC) of the FCV of any serious
adverse event within 24 hours of learning about it.
A non-serious adverse event will be classified as follows:
1. Mild: The patients are aware of their symptoms and/or
signs, but those are tolerable. They do not require medical
intervention or specific treatment.
2. Moderate: Patients present troubles that interfere with
their daily activities. They require medical intervention or
specific treatment.
3. Severe: The patients are unable to work or to attend
their daily activities. They require medical intervention or
specific treatment.
The possible relationship between the adverse events and
the tested medication will be classified by the investigator
on the basis of his/her clinical judgment and the follow-
ing definitions:
1. Definitely related: Event can be fully explained by the
administration of the tested medication.
2. Probably related: Event is most likely to be explained by
the administration of the tested medication rather than
other medications or by the patient's clinical state.
3. Possibly related: Event may be explained by the admin-
istration of the tested medication or other medications or
by the patient's clinical state.
4. Not related: Event is most likely to be explained by the
patient's clinical state or other medications, rather than
the tested one.Trials 2006, 7:14 http://www.trialsjournal.com/content/7/1/14
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All the events will be reported to the AEC that, depending
on their criteria, will decide for the continuity or the with-
drawal of the patient from the study and therefore the
breaking of the code.
Although the project has been designed to minimize the
inherent risks, any adverse event related to the study med-
ications will be carefully evaluated by the AEC and the
costs generated by the required treatment will be cover by
the study.
Data analysis phase
This phase will last 6 months. After completing all the
data entry to the CFR, the results will be audited and the
detected errors evaluated and corrected by the person in
charge. The information will be entered in two different
databases by two different people and the records will be
compared to detect any discrepancy. The original CFR will
be used to correct any mistake in the database.
For the statistical analysis, Stata 8.0 will be used. The
descriptive analysis will be composed of medians and
proportions according to the nature of the variables, with
its respective 95% confidence intervals. As a dispersion
measurement the standard deviation will be calculated.
The distribution of the variables will be studied using the
Shapiro-Wilk test. To detect any difference between the
groups, a T-test or a Wilcoxon test will be performed
according to its distribution. The categorical variables will
be compared using the Chi2 test or the exact Fisher's test.
If required, a model of multiple logistic regressions or a
covariance analysis will be done.
Two interim analyses will be performed when 35% and
70% of the calculated sample is collected, with the objec-
tive of determining the differences in effectiveness and
safety between the treatments.
Endpoints
At the end of the study two endpoints will be evaluated:
1. Successful Treatment:
a. Complete reepithelization three months after the begin-
ning of the treatment.
b. Absence of reactivation and affections of the mucous
membranes during the 6 months of the study.
2. Treatment Failure:
a. Incomplete reepithelization three months after the
beginning of the treatment.
b. Increase in the size of the ulcer by more than 50% in
relation to the last clinical evaluation
c. Reactivation and/or affections of the mucous mem-
branes during the 6 months of the study.
Final report
At the end of the study the results will be evaluated and
discussed and a final report presented to COLCIENCIAS,
entity that is sponsoring the project. The relevant results
will be published in both, national and international
journals, and presented in congresses and scientific meet-
ings.
Ethical aspects
This study will be conducted in accordance with the Dec-
laration of Helsinki and with the Colombian legislation
as per the Resolution 8430/93 from the Ministry of
Health. Prior to the admission of the patients in the study,
the objectives and the methodology will be explained and
the informed consent obtained. The study was approved
Table 3: Toxicity grading scale for determining the severity of laboratory adverse events
Parameter Normal Range# Grade for Abnormal Results (Value or Change from Reference)
(Grade 0) Mild (Grade 1) Moderate (Grade 
2)
Severe (Grade 3)* Severe (Grade 4)*
ALT (GPT) 5 – 40 U/L >ULN – 2.5 × ULN >2.5 – 5.0 × ULN >5.0 – 20.0 × ULN >20.0 × ULN
AST (GOT) 6 – 35 U/L >ULN – 2.5 × ULN >2.5 – 5.0 × ULN >5.0 – 20.0 × ULN >20.0 × ULN
Creatinine 0.7 – 1.5 mg/L >ULN – 1.5 × ULN >1.5 – 3.0 × ULN >3.0 – 6.0 × ULN >6.0 × ULN
Pancreatic 
Amylase
<120 U/L >ULN – 1.5 × ULN >1.5 – 2.0 × ULN >2.0 – 5.0 × ULN >5.0 × ULN
# Normal lab ranges may vary from time to time depending on the reagent/kit used at local lab. Every time the normal ranges change, the 
laboratory will fax a copy of the "normal ranges" for that date to the Investigators. To respect confidentiality, the subject's name will be covered.
* Grade 3 or 4 lab value: Suspend treatment.
ULN: Upper limit of normal range
Ref: Toxicity Grading based on CTCAE v3.0 DCTD, NCI, NIH, DHHS December 12, 2003 http://ctep.cancer.gov.Trials 2006, 7:14 http://www.trialsjournal.com/content/7/1/14
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by the Research Ethic Committee of the Cardiovascular
Foundation of Colombia (Act# 105/January 28/2005).
The right to confidentiality of the patients will be main-
tained in all the phases of the study.
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